BioCryst Pharmaceuticals is closing its Discovery Center of Excellence in Birmingham by the end of 2026. This change is part of a broader shift to stop internal research and focus instead on external partnerships and licensing

“The company is moving away from in-house lab work to find new treatments through outside deals,” CEO Charlie Gayer said.

Closing the Birmingham site and ending internal programs reduces expected 2026 non-GAAP operating expenses to about $420 million.